Upcoming new
Read more about the active trials currently enrolling NEW that MedVadis Research is involved with. Contact us anytime if you would like to volunteer or have any questions.
Adult Migraine
Study ID 300
A Phase 4, interventional, open-label trial, investigating the effectiveness of eptinezumab in participants with migraine and previous inadequate response to CGRP-targeting therapies
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: Male & Female
Age: 18 Years to 75 Years
Enrolling Now!
Study ID 291
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension
Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: Female
Age: 18 Years and Older
Enrolling Now!
Study ID 301
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine
In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Now!
Study ID 302
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine
In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Now!
Study ID 273
The MONARCH (Multicenter Occipital Neuralgia and Cervicogenic Headache) Case Series Study: Treatment of Head Pain with the SPRINT® Peripheral Nerve Stimulation (PNS) System
The purpose of this study is to learn if pain can be relieved by delivering small amounts of electricity (called "electrical stimulation") to the nerves at the top of the neck. This study will use a device called the SPRINT® PNS System. PNS stands for peripheral nerve stimulation (PNS). This device is cleared by the FDA for up to 60 days of use for relief of chronic or acute pain.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID Trial ID
Trial Title. This is a Trial Title. It is Used to Describe the Clinical Trial. It is typically a Shorter Version of the Scientific Description.
Trial Description. This Phase 12 Extension trial will evaluate the efficacy and safety of GRE-472 for obesity prevention in adults who suffer from twenty seven or more pounds above ideal body weight per month. The study will enroll approximately 2,345 patients across approximately 432 sites in the United States, Canada, Cameroon and Australia from the Phase 9 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of BAC-231 utilizing the Company's novel injection paradigm.
Medical Conditions:
Trial Medical Condition
Related Conditions: Trial Medical Condition
Sex/Gender: Trial Gender
Age: Trial Age Range
Trial Enrollment Status!
Study ID 235
A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine
Medical Conditions:
Related Conditions:
Sex/Gender:
Age:
Study Completed!
Study ID 240
Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV- 3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 245
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender:
Age:
Study Completed!
Study ID 250
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Medical Conditions:
Adult Migraine
Related Conditions: Adult Migraine
Sex/Gender:
Age:
Study Completed!
ALS
Study ID 265
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Medical Conditions:
ALS
Related Conditions: ALS
Sex/Gender: Male & Female
Age: 18 Years to 85 Years
Enrolling Now!
Alzheimer's Disease
Study ID 259
Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 55 Years to 80 Years
Enrolling Now!
Study ID 288
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 50 Years to 89 Years
Enrolling Now!
Study ID 251
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
"The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. Trial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up."
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 60 Years to 85 Years
Enrollment Complete!
Study ID 257
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 65 Years to 80 Years
Enrollment Complete!
Study ID 274
Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 60 Years to 85 Years
Enrollment Complete!
Study ID 282
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer’s Disease
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 55 Years to 85 Years
Enrollment Complete!
Study ID 298
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: Male & Female
Age: 55 Years to 80 Years
Enrollment Complete!
Study ID 258
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender:
Age:
Study Completed!
Study ID 263
A Phase 3, Randomized, Double-Blind Placebo-Controlled Parallel-Group 76-Week Study Evaluating The Safety And Efficacy Of Two Doses Of Simufilam In Subjects With Mild-To-Moderate Alzheimer's Disease
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender:
Age:
Study Completed!
Study ID 277
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer’s Disease
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender:
Age:
Study Completed!
Chronic Low Back Pain
Study ID 299
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Now!
Study ID 236
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Soon!
Study ID 238
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 247
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 255
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 271
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Study ID 287
A Phase 2, Randomized, Double-blind, Placebocontrolled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects with Painful Lumbosacral Radiculopathy
Medical Conditions:
Chronic Back Pain
Related Conditions: Chronic Back Pain
Sex/Gender:
Age:
Study Completed!
Chronic Knee Pain
Study ID 305
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial (ATTAIN-OA PAIN)
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Soon!
Study ID 305
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial (ATTAIN-OA PAIN)
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Soon!
Study ID 236
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Soon!
Study ID 278
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 281
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4)
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 237
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Study Completed!
Study ID 246
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Study Completed!
Study ID 254
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Study Completed!
Study ID 270
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender:
Age:
Study Completed!
Diabetic Neuropathy
Study ID 295
A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects with Pain Associated with Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender: Male & Female
Age: 18 Years to 80 Years
Enrolling Now!
Study ID 296
A Phase 3, Open-label Study Evaluating the Longterm Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender: Male & Female
Age: 18 Years to 80 Years
Enrolling Now!
Study ID 279
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 239
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 248
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 256
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 260
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 268
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain (NEPTUNE-17)
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 272
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Study ID 286
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants with Diabetic Peripheral Neuropathic Pain
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender:
Age:
Study Completed!
Obesity
Study ID 299
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Now!
Study ID 305
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial (ATTAIN-OA PAIN)
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrolling Soon!
Study ID 279
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 280
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 281
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4)
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Study ID 278
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants without Type 2 Diabetes who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: Male & Female
Age: 18 Years and Older
Enrollment Complete!
Gout
Study ID 303
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
Medical Conditions:
Gout
Related Conditions: Gout
Sex/Gender: Male & Female
Age: 18 Years to 75 Years
Enrolling Soon!
Study ID 304
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Tophaceous Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
Medical Conditions:
Gout
Related Conditions: Gout
Sex/Gender: Male & Female
Age: 18 Years to 75 Years
Enrolling Soon!